Ontario start-up to commercialize smart nanomedicine technology for brain cancer
FACIT deploys Ontario First capital, enables rising local start-up to reach critical value inflection point. FACIT has previously supported Nanology, spun out of the University of Toronto, through both its early-stage Prospects Oncology Fund and seed-stage Compass Rose Oncology Fund.
FACIT Features: Notch Therapeutics Closes $85M USD Series A for Renewable Stem Cell-Derived Cancer Immunotherapies
Notch is a Canadian biotech incubated by Ontario-based Centre for Commercialization of Regenerative Medicine (CCRM)
The financing is one of the largest Series A financing round in Canadian biotech history, notably at a time of heightened interest by Ontario in commercializing homegrown intellectual property.
FACIT crowns 2021 winner of Falcons’ Fortunes pitch competition; announces follow-on investment in 2020 winner, Bridge7 Oncology
Showcasing Ontario’s emerging biotech entrepreneurs and driving value from intellectual property
FACIT's Prospects Oncology Fund and its annual pitch competition help to advance Ontario oncology innovations.
FACIT welcomes life sciences executive Ken Newport to its Board; Director Shana Kelley appointed to the Order of Ontario
Blend of scientific, industry, investment and entrepreneurial expertise complements FACIT’s leading role in growing Ontario’s life sciences commercialization
Mr. Newport is a passionate executive and advocate of Ontario’s life science sector, having decades of leadership experience in both public and private ventures.
FACIT fuels promising made-in-Ontario breast cancer therapeutic and medtech innovations through Prospects Oncology Fund
Ontario First capital supports early stage commercialization of cancer intellectual property
The newest recipients of Ontario First seed capital include Dr. Rebecca Laposa of the University of Toronto, as well as London-based start-up Multi-Magnetics Inc.
FACIT Features: Triphase Accelerator reports positive interim results of lead compound in Phase 1 Clinical Trial for Lymphoma
The encouraging study results includes six complete remissions in previously-treated lymphoma patients.
FACIT congratulates Triphase Accelerator on interim results from its ongoing Phase 1 multi-center, open-label monotherapy study of TRPH-222.
FACIT Features: DNAstack to lead and develop COVID Cloud for Canada’s Digital Technology Supercluster
The COVID Cloud will enable accelerated and more insightful interpretation of COVID-19, leading to increased preparedness for future outbreaks, and identification of potential treatments.
FACIT is pleased to accept the invitation to join the national consortium as Lead Commercialization Advisor.
FACIT Features: Portfolio company KA Imaging secures FDA approval for portable dual-energy x-ray detector
Reveal™ enables bone and soft tissue differentiation in a single, highly sensitive x-ray exposure.
Since FACIT’s early seed investment in KA Imaging, the company has greatly expanded its IP portfolio, as well as the number of highly skilled jobs it has brought to Ontario.
Following other successful Canadian biotech IPOs this year, Fusion’s IPO represents the largest by an Ontario biotechnology company
FACIT congratulates Hamilton-based Fusion Pharma (NASDAQ: FUSN) on its initial public offering (IPO) with shares of the company beginning to trade on the Nasdaq Global Market exchange today.
Replica Analytics and Sunnybrook’s Czarnota Lab receive key seed funding to de-risk Ontario intellectual property
FACIT’s investments strategically address the seed-stage gap experienced by Ontario’s life sciences sector, fueling promising cancer breakthroughs towards a value inflection point and helping local start-ups establish and anchor jobs in the province.
FACIT recognized with 2020 Venture Capital Regional Impact Award by the Canadian Venture Capital & Private Equity Association (CVCA)
Award acknowledges FACIT’s commercialization impact in growing Ontario’s life sciences industry
FACIT’s award was specifically related to the 2019 historic US$1B partnership between its portfolio companies, Propellon Therapeutics and Triphase Accelerator, and US pharma giant Celgene (acquired by Bristol-Myers Squibb Company).
FACIT Features: OICR leads international team to generate world’s most comprehensive cancer genome map
FACIT congratulates its strategic partner, OICR, on its leading role in completing an unprecedented, multi-institutional study of whole cancer genomes, spanning 10 years.
The output from this global study vastly improves the fundamental understanding of cancer and will provide guidance and new directions for its diagnosis and treatment.
FACIT Announces Artificial Intelligence pitch as Winner of 2020 Falcons’ Fortunes on World Cancer Day
Annual cancer-focused competition showcases Ontario’s emerging entrepreneurs and FACIT’s commitment to drive local value from intellectual property
The winning pitch was delivered by Mr. Meir Dick of Bridge7 Oncology. This local start-up is scaling clinical expertise with AI to automate and improve the efficiency, consistency and quality of delivering cancer care.
"Commercializing innovation for cancer patients and economic impact", February 4, 2020
Prospects proof-of-concept funding elevates Ontario companies to seed stage investment
Spun out of the University of Toronto, both start-ups have previously received funding through FACIT’s proof-of-concept Prospects Fund.
FACIT Features: Fusion Pharma Attracts $20M USD Commitment from Canada Pension Plan Investment Board
FACIT congratulates Fusion Pharma on securing additional investment from CPPIB, adding to the $105M USD Series B announced in April 2019.
The financing enables the company to continue leveraging strong Ontario science, as well as develop manufacturing and local career opportunities for scientists and trainees...
FACIT congratulates Turnstone Biologics, a startup co-founded by FACIT, and Takeda Pharmaceutical Company Limited on their global collaboration and license agreement.
The strategic collaboration will focus on developing multiple products from Turnstone’s next-gen oncolytic viral immunotherapies, marking an important alliance for both companies in the fight against cancer.
FACIT congratulates Dr. Trevor Pugh, OICR’s Director of Genomics and Senior Principal Investigator, on being one of ten winners of the 2019 TD Ready Challenge.
The $1M award will support Dr. Pugh’s development work towards advancing a blood-based diagnostic for early cancer detection, in collaboration with Dr. Raymond Kim of the Princess Margaret Cancer Centre.
FACIT, Triphase Accelerator, Celgene, and OICR to present at Canadian Science Policy Conference 2019
Panel focuses on the recent $1B USD FACIT-Triphase Accelerator-Celgene partnership and its impact on Canadian healthcare commercialization
Titled “Ontario First in the innovation economy: impacts of a $1B USD public-private-partnership (PPP) on Canadian healthcare commercialization”, the panel seeks to highlight the outcomes and key lessons from this unprecedented partnership.
FACIT launches assessment of venture philanthropy models to scale Canadian commercialization of cancer research
Ms. Donna Parr and Dr. Niclas Stiernholm recruited to broaden public/private equity expertise
Scaling FACIT’s impact requires new partners and expanded expertise in the management of investments and equity markets. To that end, FACIT has recruited two seasoned executives through its Executive-in-Residence (EIR) Program.
Next generation liquid biopsy platform to revolutionize companion diagnostics
Cellular Analytics is founded upon a proprietary microfluidic platform that enables molecular characterization of cancer at the level of single circulating tumour cells.
FACIT Features: Portfolio company KA Imaging secures Series A financing and new global strategic partner
Partnership couples KA Imaging’s portable multi-energy x-ray detector technology with advanced manufacturing expertise.
New partnership will provide the Ontario-based start up with both capital and advanced manufacturing expertise to accelerate its portable multi-energy x-ray detector technology.
FACIT’s Prospects Oncology Fund invests in Ontario-developed medical device and novel therapeutic platform technologies
Niche early-stage investment program seeds Ontario’s developing pipeline of oncology assets
FACIT announces investments in Xpan Inc. and innovations from OICR and the University of Toronto...
FACIT congratulates its strategic partner OICR on their recent industrial collaboration with Thermo Fisher Scientific and Genome Canada
New collaboration will develop targeted next generation sequencing (NGS) assays and software to improve cancer management...
$40M in seed investments leverages 19x new capital into Ontario cancer biotechnology commercialization
FACIT’s network of industry partners and investors are becoming increasingly aware of the top-tier quality of Ontario’s innovations, which has been integral in attracting the $750M follow-on investment.
Entrepreneurs from Ontario’s Nanology Labs and Xpan Inc. receive FACIT investment for early-stage cancer innovations
Latest recipients slated to accelerate Ontario’s commercialization momentum are a 2018 finalist and 2019’s winner of FACIT’s Falcons’ Fortunes pitch competition.
FACIT is pleased to announce recent successes in its mission to help bridge the capital gap often experienced by early-stage entrepreneurs.
FACIT congratulates portfolio company Fusion Pharma on the addition of top-tier healthcare investors in support of their cancer-targeting, next-gen radiotherapies.
Ontario First investor FACIT congratulates portfolio company Fusion Pharmaceuticals, a clinical-stage biotech developing novel targeted alpha radiotherapies...
FACIT Features: Triphase Accelerator initiates Phase 1 clinical trial of next-gen ADC for B-cell lymphoma
FACIT congratulates portfolio company Triphase Accelerator on significant clinical development milestone.
Triphase Accelerator has dosed their first patient in a Phase 1 clinical trial of TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma.
FACIT Features: Portfolio company Fusion Pharma launches Phase 1 trial for next-gen radiotherapeutic
FACIT congratulates portfolio company Fusion Pharma on significant clinical development milestone.
Fusion Pharma announced the first patient dosing with lead candidate in Phase 1 trial for solid tumors.
"For innovation, open science means open for business", February 6, 2019
"U.S. biotech giant Celgene invests in Ontario-developed blood-cancer drug in potential $1-billion deal", January 29, 2019
FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
Largest transaction to date for Canadian-discovered preclinical asset arises from Ontario collaborators
Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia.
Capital leverages Ontario’s strengths in genomics and informatics, deepens FACIT’s tech portfolio
FACIT's Compass Rose Oncology Fund is providing the follow-on investment. DNAstack also previously received capital from FACIT's early-stage Prospects Oncology Fund, illustrating FACIT's strategy to ensure promising companies grow roots and scale up in Ontario.
FACIT Features: Portfolio company KA Imaging launches first-in-human pilot study to test lung screening x-ray
FACIT congratulates portfolio company KA Imaging on significant clinical development milestone.
KA Imaging, a recent Prospects Fund recipient, is partnering with Grand River Hospital to conduct a pilot study on the use of a high-resolution multi-energy digital x-ray imager for patients with lung nodules.
Strategic appointments of seasoned entrepreneurs add expertise and strengthen governance
Both leaders are passionate supporters of the Ontario life science sector, have broad industry experience and decades of work with entrepreneurial ventures.
Prospects Oncology Fund seeds developing pipeline of Ontario-based biotech innovations
With an expanding portfolio of breakthrough innovations, FACIT is committed to supporting Ontario entrepreneurs through the latest round of its Prospects Oncology Fund.
World-leading genomics cloud computing group builds clinical tool for cancer care in Ontario
Derived from a leading oncology bio-computing group and leveraging insights from the world’s largest cancer genomics projects, Ziliomics develops web-based, modular software platforms that help physicians make actionable treatment decisions for patients living with cancer.
Entrepreneur adds US oncology management experience to Ontario commercialization.
Dr O’Neill brings two decades of cancer drug development and seed stage investment experience, as well as an extensive business network in pharma and biotech.
Dr. Laszlo Radvanyi's industry expertise & network aligns well with OICR and FACIT's shared vision.
FACIT looks forward to working with Dr. Radvanyi on translating Ontario’s breakthrough oncology innovations.
Restorative Breast Cancer Solution Start-Up Wins the 2018 FACIT Pitch Competition.
Biotechnology competition modeled after popular TV program Dragons' Den.
FACIT’s Prospects Oncology Fund invests $450k in promising Ontario breakthrough technologies.
Investment supports emerging entrepreneurial scientists and critical proof-of-principle studies.
Saying goodbye to FACIT's friend and visionary-in-chief.
Jeff was a fantastic leader in the OICR-FACIT family and the broader Ontario life sciences community.
Seeding world class oncology innovation: a look back at 2017
We hope 2017 was a prosperous year for you, our partners in health innovation. While FACIT had many successes this year.....
FACIT congratulates OICR on launching CTIP to drive Ontario's most promising cancer drugs towards the clinic.
The Clinical Therapeutics Innovation Pipeline (CTIP) will support the local translation of Ontario discoveries into therapies with the potential for improving the lives of patients with cancer. Ten projects were selected in this highly competitive funding round, and reflect the strength of the province’s collaborative network and drug discoveries.
FACIT expands Board to advance mandate to drive Ontario cancer breakthroughs.
New Trustees join existing Trustees, Mr. Greg Gubitz and Mr. John Morrison, bringing additional financial, entrepreneurial and biotech industry expertise.
FACIT Congratulates Portfolio Company Turnstone Biologics on Transformative Collaboration with AbbVie
Turnstone Biologics, a startup co-founded by FACIT, announced a research, option and license agreement with AbbVie Inc. for up to three of Turnstone's next-gen oncolytic viral immunotherapies. This partnership deepens the Ontario roots established by FACIT and its co-founders, expanding the scale of innovative research and local career opportunities for scientists.
Addition of new investors builds on Ontario’s next-gen radiotherapies and cancer innovations
FACIT congratulates Fusion on completing the second closing of their Series A, now oversubscribed at US$46M, with new investors joining including Adams Street Partners, Seroba Life Sciences, and Varian Medical Systems Inc. FACIT participated in both, this latest closing and as an early seed investor in Fusion.
FACIT Launches Cross-border Campaign to Recruit Clinical Scientists and Biotechnology Industry Executives
Initiative targets expats for growing oncology company portfolio in Ontario
FACIT is expanding and updating its database of US-based industry advisors for roles ranging from investment diligence to full time management roles in Ontario-based biotech start-ups.
FACIT invests first round of Prospects Fund in Radialis Medical, KA Imaging, and DNAstack.
Ontario start-ups Radialis Medical of Thunder Bay, KA Imaging of Kitchener, and DNAstack of Toronto are the first to receive capital from FACIT's new Prospects Oncology Fund for proof-of-concept development of breakthrough cancer technologies.
Anil Amlani expands FACIT’s oncology expertise in medical device sector
Anil Amlani joins FACIT with strong executive and transactional experience, broadening the available expertise to provide critical senior management and leadership to create and nurture FACIT start-ups in Ontario.
First Patient Treated in Turnstone's Lung Cancer Trial Combining Novel Viral Cancer Therapy with Approved Checkpoint Inhibitor
Combination of Turnstone's oncolytic viral immunotherapy with checkpoint inhibitors showed promising results in preclinical testing.
Turnstone announced that treatment has been initiated on the first patient in the company's Phase I/II clinical trial combining its novel oncolytic viral immunotherapy agent, MG1-MAGEA3, with pembrolizumab, an approved anti-PD-1 antibody.
Seed financing of CAD$3.0M positions first-in-class WDR5 cancer therapy for clinical development.
Seed funding from FACIT enables Propellon to accelerate the nomination of a candidate drug and position the Company for financing and/or entering a strategic partnership for clinical trials in patients with haematological cancers.
New evergreen fund to help Ontario discoveries reach seed-stage funding faster.
FACIT announces the launch of The Prospects Oncology Fund, designed to advance early-stage Ontario cancer discoveries by supporting the proof-of-concept studies needed to attract seed-stage investment.
Financing leverages and strengthens Ontario’s next-generation radiotherapeutics expertise, products.
FACIT and OICR report that Fusion Pharmaceuticals Inc. has closed a US$25M Series A financing, with Johnson & Johnson Innovation – JJDC, Inc. as the lead investor. Additionally, new investors include venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well as founding investor FACIT.
The new collaboration provides Celgene with an option to acquire all Triphase Accelerator’s assets relating to TRPH 222 (CD22-4AP), an antibody-drug conjugate in development for lymphoma.
Triphase Accelerator Corporation announced a new strategic collaboration with Celgene Corporation, that provides Celgene with an option to acquire all Triphase Accelerator’s assets relating to TRPH 222 (CD22-4AP), an antibody-drug conjugate in development for lymphoma.
Marizomib is a novel brain-penetrant proteasome inhibitor in development for patients with glioblastoma and relapsed and/or refractory multiple myeloma
Triphase Accelerator Announces that Celgene Corporation has acquired the company's assets related to its proteasome inhibitor, marizomib, which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.
OrbiMed, Versant-led round continues commercialization success for Turnstone’s cancer therapies
FACIT-created Turnstone Biologics raises USD $41M, one of the largest Series B rounds for a Canadian biotech, attracting blue-chip healthcare investors to accelerate commercialization of proprietary oncolytic viral immunotherapies.
Catalent Biologics and Triphase Accelerator Corporation Announce License Agreement to Advance SMARTag™ ADC to Clinic
Triphase will obtain worldwide rights to further develop Catalent's proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent’s wholly owned subsidiary, Redwood Bioscience, Inc., using its SMARTag™ technology platform.
FACIT forms biotechnology company for OICR-discovered first-in-class epigenetic modifiers
The creation of Propellon to manage the development and commercialization of a portfolio of first-in-class epigenetic therapeutics, WDR5 inhibitors, enables important development activities including attracting private sector investment and industry partnerships.
Integrating innovative data privacy expertise with a global healthcare information & technology service leader, strengthening and driving Ontario’s digital healthcare security footprint.
The transaction combines Privacy Analytics’ leading edge expertise in health data anonymization and de-identification with IMS Health’s broad range of healthcare information, technology and services solutions.
Two New Clinical Trials to Be Initiated for Recurrent and Newly Diagnosed Malignant Gliomas
Triphase is expanding its current collaboration with Celgene in the development of marizomib for the potential treatment of malignant gliomas.
Combined entity creates strong foundation for leading Canadian immuno-oncology company.
Trillium Therapeutics has acquired all of the outstanding shares of privately-held Fluorinov Pharma, a FACIT portfolio company.
Image-guided medicines for hard to treat cancers built using next generation medical isotopes.
FACIT's investment will support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer.
First-in-class epigenetic modifiers discovered by OICR positioned for collaborative development.
FACIT acquires exclusive rights to a portfolio of first-in-class WDR5 inhibitors for the treatment of mixed lineage leukemia.
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
Orphan drug designation granted by the FDA recognizes the unique potential of marizomib to benefit patients with malignant glioma.
Triphase is evaluating marizomib in combination with bevacizumab in patients with recurrent glioblastoma.
FACIT Startup Turnstone Biologics Closes $11M Financing, Secures Additional Capital Commitment, and Adds Strong Management
Completion of a Series A financing round enables appointment of Dr. Sammy Farah as CEO and Dr. Brian Lichty as CTO.
Versant Ventures-led investment accelerates development, broadens oncolytic viral immunotherapy potential.
OICR, UHN, Novera Therapeutics Announce Collaboration with Johnson & Johnson Innovation on Drug Discovery and Development for Haematological Cancers
Research Collaboration and Option and License Agreement Reach Approximately $450 Million Cdn.
OICR, UHN, Novera Therapeutics collaborate with Johnson & Johnson Innovation to accelerate the development drug candidates for haematological cancers.
Marabex™ trial to assess the safety of a novel tumour-targeted oncolytic virus vaccine in patients with advanced solid tumours
Turnstone Biologics Inc., a FACIT portfolio company, has announced the ongoing enrollment of the Marabex™ clinical trial assessing the safety and immune responses in patients with advanced or metastatic, MAGE-A3-expressing solid tumours.
Fluorinov Pharma and FACIT announce the appointment of Luke M. Beshar, to Fluorinov's Board of Directors.
Mr. Beshar's appointment strengthens Fluorinov’s leadership team, adding financial and pharmaceutical industry expertise as Fluorinov accelerates its clinical development activities.
Turnstone Biologics Inc. to Accelerate Clinical and Commercial Translation of Cancer Immunotherapies
FACIT partners with Ontario researchers to create new company.
FACIT and its partners are pleased to announce the formation of Turnstone Biologics Inc., a biotechnology company focussed on developing treatments for cancer that harness the patient’s own immune system.
Roger J Garceau Joins Fluorinov Board, Adds Clinical Expertise to Bromodomain Program and Oncology Pipeline
Fluorinov Pharma and FACIT announce the appointment of Dr. Roger J Garceau, to Fluorinov's Board of Directors.
With extensive experience guiding biotech companies in matters including corporate development and clinical strategy, Dr. Garceau's appointment strengthens Fluorinov’s leadership team and adds significant regulatory expertise as Fluorinov transitions to clinical development.
Fluorinov Pharma and FACIT Announce Investment in Breakthrough Bromodomain Inhibitors for the Treatment of Cancers
FACIT invests in Fluorinov Pharma's novel anti-cancer bromodomain inhibitors and disruptive potential of its technology platform.
TORONTO, ON (January 07, 2015) – FACIT and Fluorinov Pharma announced today an investment in the development of highly potent inhibitors of key bromodomain targets.
FACIT is planning its Falcons’ Fortunes pitch competition in 2015.
On Wednesday, March 11, 2015, FACIT invites you to pitch your idea to a panel of sharp-eyed yet friendly investors. Hosted by the commercially savvy FACIT Falcons, this event is offering $50,000 in Catalyst Funding to invest in the most promising oncology research idea.
FACIT-supported Xagenic Inc is a chip-based diagnostic screening company.
BDC Capital joined as a new investor and Dion Madsen, Senior Managing Partner at BDC Capital, will join Xagenic’s Board of Directors.
XLV Diagnostics Inc. specializes in low-cost, next-generation digital mammography machines.
XLV, a MaRS Innovation start-up company based in Thunder Bay, closed a $3 million Series A investment round with Boston-based Bernard M. Gordon Charitable Remainder Unitrust.
Fluorinov has developed three structurally distinct candidate drugs intended to treat cancer pain and brain cancer-related epilepsy.
The candidate drugs have shown excellent preliminary safety profiles, improved treatment and expect to have fewer sedative side effects.
High-parameter single-cell protein analysis platform joins with industry-leading single-cell genomics platforms.
With the closing of the acquisition, Fluidigm adds a high-parameter single-cell protein analysis platform to its industry-leading single-cell genomics platforms.
A Unique Collaboration of Life Science Leaders has formed Triphase Accelerator Corporation to be an Oncology Development Accelerator.
Triphase was spun out of the Ontario Institute for Cancer Research to develop and advance late pre-clinical, Phase I or early Phase II potential products.
Funding of $1.5 million will be used to further develop a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects.
Cellax™, invented by OICR researchers, is a drug-polymer conjugate based on the proprietary NanoCMC™ technology.
OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers.
OICR will provide $1.5 million for the development of FV-162, a highly potent, orally-delivered small molecule proteasome inhibitor for multiple myeloma and some forms of Non-Hodgkin’s lymphoma.
OICR-supported Xagenic Inc is a new chip-based diagnostic screening company.
Investors in the Series A round included CTI Life Sciences Fund L.P., Qiagen N.V. and Ontario Capital Growth Corporation through its Emerging Technologies Fund.